ArticleClinical rheumatology2026
Circulating levels of TL1A and its decoy receptor DcR3 in systemic sclerosis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
INTRODUCTION/
objectiveTumor necrosis factor-like cytokine 1A (TL1A, TNFSF15) is a profibrotic and proinflammatory cytokine. Experimental evidence implicates TL1A-mediated interactions in interstitial lung disease (ILD); such interactions are disrupted by decoy receptor 3 (DcR3) binding to TL1A. We examined the potential clinical value of circulating TL1A and DcR3 levels in systemic sclerosis (SSc).
methodsConsecutive unselected patients with SSc (n = 41) of varying disease duration, severity, and treatment modalities; individuals with primary Raynaud's phenomenon (pRP) (n = 52); and apparently healthy individuals (n = 49) were studied. Serum TL1A and DcR3 levels were measured by ELISA.
resultsTL1A levels were increased in SSc patients compared to healthy individuals whereas DcR3 levels were increased in SSc compared to both pRP and healthy individuals (all p < 0.001). Clinical features, pulmonary function tests, and treatment modalities were analyzed at baseline and annually for two consecutive years. Using receiver operating characteristic (ROC) analysis and the MINIMISE endpoint for mortality and morbidity we found that baseline serum levels of DcR3, but not TL1A, were predictive of SSc progression over 2 years (AUC = 0.684, p = 0.04). While no associations between TL1A levels and disease characteristics were noted, patients with DcR3 levels above the ROC-defined cut-off had significantly higher erythrocyte sedimentation rate, higher prevalence of ILD confirmed by high resolution chest computed tomography, and lower diffusion capacity for carbon monoxide.
conclusionsIncreased circulating DcR3 levels are associated with SSc-ILD in unselected patients and may serve as a biomarker of disease progression. Further studies are needed to explore the clinical value in selected SSc patient subgroups. Keypoints • TL1A and DcR3 are elevated in the serum of patients with systemic sclerosis. • DcR3 levels are associated with SSc-ILD and higher systemic inflammation. • Circulating DcR3 levels may serve as a prognostic biomarker in SSc.
Indexed as
Identifiers
42622765What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.